Paliativos

PO535
Palliative radiotherapy in head neck cancer. Quad-shot schedule
Mari Ángeles González Ruiz 1 , Amanda Ruiz Herrero 1 , Ana Torres García 1 , Cristina Cruz Muñoz 1 , Joaquín José
Cabrera Rodríguez 1
1
Residente Oncología Radioterápica, Badajoz
Introduction: Several palliative radiotherapy regimens has been described for incurable head neck cancer (HNC).
The Quad-shot (Q-S) is a hypofractionated schedule with favorable therapeutic ratio (tumoral response/treatment
toxicity).
This regimen consist on 14 Gy in four fractions, twice a day, for two consecutive days. This cycle is repeated every
three weeks, maximum of three (42 Gy).
Objective: Endpoints: Primary, to evaluate quality of life (QoL) and control of symptoms. Secondary, to evaluate
toxicity.
Methods: Descriptive study of 2 patients (pts) treated from November to January 2015. They had recurrence of
HNC located at retropharyngeal space and maxillary sinus respectively. QoL was evaluated with EORTC QLQ-C30 and
symptoms with Edmonton Symptom Assessment System (ESAS). Pts rated QoL and symptoms before treatment and
three weeks after each cycle. Toxicity was evaluated with Common Terminology Critera of Adverse Events (CTCAE).
Results: First patient rated his pain in 8 of 10 points according ESAS and QoL in 4 of 7 points. He didn´t has very
severe symptoms in terms of tiredness, nausea, owsiness, anorexia, dyspnea or depression. After the first cycle of
treatment, he rated his pain in 5 of 10 points and QoL in 5 points. After the second cycle, symptons and QoL were
rated in the same score. Second patient didn´t has very severe symptoms and rated her QoL in 4 of 7 points. After
the first cycle, the symptoms score were similar and QoL the same. After the second cycle, she rated her QoL in 5 of
7 points and the symptons score were similar. Both pts are pending to receive the next cycle of treatment. Toxicity
was nil.
Conclusion: In spite of the study have only 2 pts, our preliminary experience support the results of trials: minimal
toxicity and
positive impact on patient´s QoL and control of symptoms.
490